Top

Published in:

Open Access 01-12-2013 | Review

Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases

Authors: Xin He, Zhigang Chen, Yangyan Jiang, Xi Qiu, Xiaoying Zhao

Published in: Journal of Hematology & Oncology | Issue 1/2013

Abstract

The human c-mpl gene (MPL) plays an important role in the development of megakaryocytes and platelets as well as the self-renewal of haematopoietic stem cells. However, numerous MPL mutations have been identified in haematopoietic diseases. These mutations alter the normal regulatory mechanisms and lead to autonomous activation or signalling deficiencies. In this review, we summarise 59 different MPL mutations and classify these mutations into four different groups according to the associated diseases and mutation rates. Using this classification, we clearly distinguish four diverse types of MPL mutations and obtain a deep understand of their clinical significance. This will prove to be useful for both disease diagnosis and the design of individual therapy regimens based on the type of MPL mutations.

Available only for authorised users

Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 1990, 63: 1137-1147. 10.1016/0092-8674(90)90410-G.CrossRefPubMed

Vigon I, Mornon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S, Souyri M: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A. 1992, 89: 5640-5644. 10.1073/pnas.89.12.5640.PubMedCentralCrossRefPubMed

Mignotte V, Vigon I, de Crevecoeur EB, Romeo PH, Lemarchandel V, Chretien S: Structure and transcription of the human c-mpl gene (MPL). Genomics. 1994, 20: 5-12. 10.1006/geno.1994.1120.CrossRefPubMed

Sabath DF, Kaushansky K, Broudy VC: Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood. 1999, 94: 365-367.PubMed

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN: An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006, 107: 1864-1871. 10.1182/blood-2005-06-2600.PubMedCentralCrossRefPubMed

Matthews EE, Thevenin D, Rogers JM, Gotow L, Lira PD, Reiter LA, Brissette WH, Engelman DM: Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J. 2011, 25: 2234-2244. 10.1096/fj.10-178673.PubMedCentralCrossRefPubMed

Drachman JG, Kaushansky K: Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A. 1997, 94: 2350-2355. 10.1073/pnas.94.6.2350.PubMedCentralCrossRefPubMed

Sattler M, Durstin MA, Frank DA, Okuda K, Kaushansky K, Salgia R, Griffin JD: The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995, 23: 1040-1048.PubMed

Pallard C, Gouilleux F, Benit L, Cocault L, Souyri M, Levy D, Groner B, Gisselbrecht S, Dusanter-Fourt I: Thrombopoietin activates a STAT5-like factor in hematopoietic cells. EMBO J. 1995, 14: 2847-2856.PubMedCentralPubMed

10.

Miyakawa Y, Oda A, Druker BJ, Miyazaki H, Handa M, Ohashi H, Ikeda Y: Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood. 1996, 87: 439-446.PubMed

11.

Sattler M, Salgia R, Durstin MA, Prasad KV, Griffin JD: Thrombopoietin induces activation of the phosphatidylinositol-3′ kinase pathway and formation of a complex containing p85PI3K and the protooncoprotein p120CBL. J Cell Physiol. 1997, 171: 28-33. 10.1002/(SICI)1097-4652(199704)171:1<28::AID-JCP4>3.0.CO;2-J.CrossRefPubMed

12.

Ritchie A, Braun SE, He J, Broxmeyer HE: Thrombopoietin-induced conformational change in p53 lies downstream of the p44/p42 mitogen activated protein kinase cascade in the human growth factor-dependent cell line M07e. Oncogene. 1999, 18: 1465-1477. 10.1038/sj.onc.1202439.CrossRefPubMed

13.

Miyakawa Y, Rojnuckarin P, Habib T, Kaushansky K: Thrombopoietin induces phosphoinositol 3-kinase activation through SHP2, Gab, and insulin receptor substrate proteins in BAF3 cells and primary murine megakaryocytes. J Biol Chem. 2001, 276: 2494-2502. 10.1074/jbc.M002633200.CrossRefPubMed

14.

Rouyez MC, Boucheron C, Gisselbrecht S, Dusanter-Fourt I, Porteu F: Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway. Mol Cell Biol. 1997, 17: 4991-5000.PubMedCentralCrossRefPubMed

15.

Rojnuckarin P, Drachman JG, Kaushansky K: Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood. 1999, 94: 1273-1282.PubMed

16.

Alexander WS, Maurer AB, Novak U, Harrison-Smith M: Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J. 1996, 15: 6531-6540.PubMedCentralPubMed

17.

Hong Y, Dumenil D, van der Loo B, Goncalves F, Vainchenker W, Erusalimsky JD: Protein kinase C mediates the mitogenic action of thrombopoietin in c-Mpl-expressing UT-7 cells. Blood. 1998, 91: 813-822.PubMed

18.

Kunitama M, Shimizu R, Yamada M, Kato T, Miyazaki H, Okada K, Miura Y, Komatsu N: Protein kinase C and c-myc gene activation pathways in thrombopoietin signal transduction. Biochem Biophys Res Commun. 1997, 231: 290-294. 10.1006/bbrc.1996.5969.CrossRefPubMed

19.

Miyakawa Y, Oda A, Druker BJ, Kato T, Miyazaki H, Handa M, Ikeda Y: Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets. Blood. 1995, 86: 23-27.PubMed

20.

de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature. 1994, 369: 533-538. 10.1038/369533a0.CrossRefPubMed

21.

Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature. 1994, 369: 568-571. 10.1038/369568a0.CrossRefPubMed

22.

Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, Tsuboi K, Nitta M, Miyazaki H, Iida S: Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004, 103: 4198-4200. 10.1182/blood-2003-10-3471.CrossRefPubMed

23.

Martinon-Torres N, Vazquez-Donsion M, Loidi L, Couselo JM: CAMT in a female with developmental delay, facial malformations and central nervous system anomalies. Pediatr Blood Cancer. 2011, 56: 452-453. 10.1002/pbc.22904.CrossRefPubMed

24.

Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, Nunes V, Foa R, Leone G, Martini M: Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica. 2010, 95: 65-70. 10.3324/haematol.2009.007542.PubMedCentralCrossRefPubMed

25.

Ballmaier M, Germeshausen M: Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011, 37: 673-681. 10.1055/s-0031-1291377.CrossRefPubMed

26.

Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Welte K: c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001, 97: 139-146. 10.1182/blood.V97.1.139.CrossRefPubMed

27.

King S, Germeshausen M, Strauss G, Welte K, Ballmaier M: Congenital amegakaryocytic thrombocytopenia: a retrospective clinical analysis of 20 patients. Br J Haematol. 2005, 131: 636-644. 10.1111/j.1365-2141.2005.05819.x.CrossRefPubMed

28.

Germeshausen M, Ballmaier M, Welte K: MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat. 2006, 27: 296-CrossRefPubMed

29.

Tijssen MR, di Summa F, van den Oudenrijn S, Zwaginga JJ, van der Schoot CE, Voermans C, de Haas M: Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia. Br J Haematol. 2008, 141: 808-813. 10.1111/j.1365-2141.2008.07139.x.CrossRefPubMed

30.

Gandhi MJ, Pendergrass TW, Cummings CC, Ihara K, Blau CA, Drachman JG: Congenital amegakaryocytic thrombocytopenia in three siblings: molecular analysis of atypical clinical presentation. Exp Hematol. 2005, 33: 1215-1221. 10.1016/j.exphem.2005.06.017.CrossRefPubMed

31.

Rose MJ, Nicol KK, Skeens MA, Gross TG, Kerlin BA: Congenital amegakaryocytic thrombocytopenia: the diagnostic importance of combining pathology with molecular genetics. Pediatr Blood Cancer. 2008, 50: 1263-1265. 10.1002/pbc.21453.CrossRefPubMed

32.

Steinberg O, Gilad G, Dgany O, Krasnov T, Zoldan M, Laor R, Kapelushnik J, Gabriel H, Churi C, Stein J: Congenital amegakaryocytic thrombocytopenia-3 novel c-MPL mutations and their phenotypic correlations. J Pediatr Hematol Oncol. 2007, 29: 822-825. 10.1097/MPH.0b013e318158152e.CrossRefPubMed

33.

Ihara K, Ishii E, Eguchi M, Takada H, Suminoe A, Good RA, Hara T: Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A. 1999, 96: 3132-3136. 10.1073/pnas.96.6.3132.PubMedCentralCrossRefPubMed

34.

Ding J, Komatsu H, Iida S, Yano H, Kusumoto S, Inagaki A, Mori F, Ri M, Ito A, Wakita A: The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood. 2009, 114: 3325-3328. 10.1182/blood-2008-04-149047.CrossRefPubMed

35.

Lee TS, Kantarjian H, Ma W, Yeh CH, Giles F, Albitar M: Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. PLoS One. 2011, 6: e23396-10.1371/journal.pone.0023396.PubMedCentralCrossRefPubMed

36.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foa R, Larocca LM: Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol. 2007, 25: 1048-1053. 10.1200/JCO.2006.08.6884.CrossRefPubMed

37.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Leone G, Foa R: The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood. 2007, 110: 3384-3386. 10.1182/blood-2007-06-094276.CrossRefPubMed

38.

Teofili L, Foa R, Giona F, Larocca LM: Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?. Haematologica. 2008, 93: 169-172. 10.3324/haematol.12002.CrossRefPubMed

39.

Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, Ding J, Komatsu H, Larocca LM, Skoda RC: Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009, 94: 1368-1374. 10.3324/haematol.2009.005918.PubMedCentralCrossRefPubMed

40.

Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL: Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A. 2004, 101: 11444-11447. 10.1073/pnas.0404241101.PubMedCentralCrossRefPubMed

41.

El-Harith el HA, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, von Neuhoff N, Becker C, Nurnberg G, Nurnberg P, Ahmed MA: Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009, 144: 185-194. 10.1111/j.1365-2141.2008.07430.x.CrossRef

42.

Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008, 22: 14-22. 10.1038/sj.leu.2404955.CrossRefPubMed

43.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S: Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005, 7: 387-397. 10.1016/j.ccr.2005.03.023.CrossRefPubMed

44.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC: A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005, 352: 1779-1790. 10.1056/NEJMoa051113.CrossRefPubMed

45.

Zhao W, Gao R, Lee J, Xing S, Ho WT, Fu X, Li S, Zhao ZJ: Relevance of JAK2V617F positivity to hematological diseases–survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011, 4: 4-10.1186/1756-8722-4-4.PubMedCentralCrossRefPubMed

46.

Zhao AH, Gao R, Zhao ZJ: Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol. 2011, 4: 40-10.1186/1756-8722-4-40.PubMedCentralCrossRefPubMed

47.

Zhao W, Du Y, Ho WT, Fu X, Zhao ZJ: JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines. Exp Hematol Oncol. 2012, 1: 15-10.1186/2162-3619-1-15.PubMedCentralCrossRefPubMed

48.

Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, Steensma DP, Elliott MA, Wolanskyj AP, Hogan WJ: MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006, 108: 3472-3476. 10.1182/blood-2006-04-018879.CrossRefPubMed

49.

Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, Cuker A, Wernig G, Moore S, Galinsky I: MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006, 3: e270-10.1371/journal.pmed.0030270.PubMedCentralCrossRefPubMed

50.

Pardanani A, Lasho TL, Finke CM, Tefferi A: Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. Am J Hematol. 2011, 86: 701-702. 10.1002/ajh.22058.CrossRefPubMed

51.

Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, Ruggeri M, Specchia G, Lo-Coco F, Delaini F: Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008, 112: 844-847. 10.1182/blood-2008-01-135897.CrossRefPubMed

52.

Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D, Dengler R, Distelrath A, Eckart M, Eckert R: Characterization of 35 new cases with four different MPLW515 mutations and essential thrombocytosis or primary myelofibrosis. Haematologica. 2009, 94: 141-144. 10.3324/haematol.13224.PubMedCentralCrossRefPubMed

53.

Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R: MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008, 112: 141-149. 10.1182/blood-2008-01-131664.CrossRefPubMed

54.

Chaligne R, James C, Tonetti C, Besancenot R, Le Couedic JP, Fava F, Mazurier F, Godin I, Maloum K, Larbret F: Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007, 110: 3735-3743. 10.1182/blood-2007-05-089003.CrossRefPubMed

55.

Pardanani A, Lasho TL, Finke C, Markovic SN, Tefferi A: Demonstration of MPLW515K, but not JAK2V617F, in in vitro expanded CD4+ T lymphocytes. Leukemia. 2007, 21: 2206-2207. 10.1038/sj.leu.2404749.CrossRefPubMed

56.

Hu WY, Zhao Y, Ishii T, Sozer S, Shi J, Zhang W, Bruno E, Hoffman R, Xu M: Haematopoietic cell lineage distribution of MPLW515L/K mutations in patients with idiopathic myelofibrosis. Br J Haematol. 2007, 137: 378-379. 10.1111/j.1365-2141.2007.06572.x.CrossRefPubMed

57.

Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, Kiladjian JJ, Socie G, Bordessoule D, Le Bousse-Kerdiles MC: New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008, 22: 1557-1566. 10.1038/leu.2008.137.CrossRefPubMed

58.

Pecquet C, Staerk J, Chaligne R, Goss V, Lee KA, Zhang X, Rush J, Van Hees J, Poirel HA, Scheiff JM: Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010, 115: 1037-1048. 10.1182/blood-2008-10-183558.CrossRefPubMed

59.

Wernig G, Kharas MG, Mullally A, Leeman DS, Okabe R, George T, Clary DO, Gilliland DG: EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012, 26: 720-727. 10.1038/leu.2011.261.CrossRefPubMed

60.

Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM: Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007, 137: 244-247. 10.1111/j.1365-2141.2007.06565.x.CrossRefPubMed

61.

Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR, Kroger N: Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant. 2010, 45: 1404-1407. 10.1038/bmt.2009.367.CrossRefPubMed

62.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007, 21: 1658-1668. 10.1038/sj.leu.2404750.CrossRefPubMed

63.

Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S: Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010, 363: 1117-1127. 10.1056/NEJMoa1002028.CrossRefPubMed

64.

Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A: Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011, 29: 789-796. 10.1200/JCO.2010.32.8021.CrossRefPubMed

65.

MN Furqan M, Lee B, Liu D: Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomarker Research. 2013, 1: 5-CrossRef

66.

Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP: UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia. 2009, 23: 610-614. 10.1038/leu.2008.249.CrossRefPubMed

67.

Schnittger S, Bacher U, Haferlach C, Dengler R, Krober A, Kern W, Haferlach T: Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia. 2008, 22: 453-455. 10.1038/sj.leu.2404909.CrossRefPubMed

68.

Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC: JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008, 93: 34-40. 10.3324/haematol.11581.CrossRefPubMed

69.

Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H: MPLW515L mutation in acute megakaryoblastic leukaemia. Leukemia. 2009, 23: 852-855. 10.1038/leu.2008.371.CrossRefPubMed

70.

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L: Activating mutations in human acute megakaryoblastic leukemia. Blood. 2008, 112: 4220-4226. 10.1182/blood-2008-01-136366.CrossRefPubMed

71.

Lambert MP, Jiang J, Batra V, Wu C, Tong W: A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. Am J Hematol. 2012, 87: 532-534. 10.1002/ajh.23138.PubMedCentralCrossRefPubMed

72.

Kawamata N, Ogawa S, Yamamoto G, Lehmann S, Levine RL, Pikman Y, Nannya Y, Sanada M, Miller CW, Gilliland DG: Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol. 2008, 36: 1471-1479. 10.1016/j.exphem.2008.06.006.CrossRefPubMed

73.

Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR: Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007, 35: 1641-1646. 10.1016/j.exphem.2007.08.010.PubMedCentralCrossRefPubMed

74.

Ohashi H, Arita K, Fukami S, Oguri K, Nagai H, Yokozawa T, Hotta T, Hanada S: Two rare MPL gene mutations in patients with essential thrombocythemia. Int J Hematol. 2009, 90: 431-432. 10.1007/s12185-009-0413-3.CrossRefPubMed

Title: Different mutations of the human c-mpl gene indicate distinct haematopoietic diseases
Authors: Xin He
Zhigang Chen
Yangyan Jiang
Xi Qiu
Xiaoying Zhao
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2013
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-6-11

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

An evolving new paradigm: endothelial cells – conditional innate immune cells

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt

Novel agents for chronic lymphocytic leukemia

miR-363-5p regulates endothelial cell properties and their communication with hematopoietic precursor cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer